Active Ingredient History
Hash oil or cannabis oil is an oleoresin obtained by the extraction of cannabis or hashish. It is a cannabis concentrate containing many of its resins and terpenes – in particular, tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids. Hash oil is usually consumed by smoking, vaporizing or eating. Preparations of hash oil may be solid or semi-liquid colloids depending on both production method and temperature and are usually identified by their appearance or characteristics. Color most commonly ranges from transparent golden or light brown, to tan or black. There are various extraction methods, most involving a solvent, such as butane or ethanol. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 2)
Acute Pain (Phase 3)
Adolescent (Phase 2)
Affect (Phase 2)
Aging (Phase 2)
Alcohol Drinking (Phase 2)
Alcohol-Induced Disorders (Phase 1/Phase 2)
Alcoholism (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2/Phase 3)
Analgesics, Opioid (Phase 4)
Anemia, Sickle Cell (Phase 2)
Anxiety (Phase 2)
Arthritis, Psoriatic (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Autism Spectrum Disorder (Phase 3)
Autistic Disorder (Phase 2)
Automobile Driving (Phase 2)
Back Pain (Phase 3)
Bipolar Disorder (Phase 2)
Brain Injuries, Traumatic (Phase 3)
Breast Neoplasms (Phase 1)
Cancer Pain (Phase 1/Phase 2)
Cannabidiol (Phase 2)
Cannabinoids (Phase 2/Phase 3)
Cannabis (Phase 4)
Carcinoma (Phase 1)
Chronic Pain (Phase 3)
Chronic Traumatic Encephalopathy (Phase 2)
Cocaine-Related Disorders (Phase 4)
Cognitive Dysfunction (Phase 2)
Colitis, Ulcerative (Phase 2)
Constipation (Phase 1)
Coronavirus (Phase 2)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 2)
Crohn Disease (Phase 2)
Dementia (Phase 2/Phase 3)
Depression (Phase 2)
Depressive Disorder, Major (Phase 2)
Diabetes Mellitus (Phase 3)
Diabetic Neuropathies (Phase 3)
Diagnosis, Dual (Psychiatry) (Phase 1)
Driving Under the Influence (Phase 1/Phase 2)
Dronabinol (Phase 2)
Drug Interactions (Phase 1)
Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)
Drug Resistant Epilepsy (Phase 3)
Dyspnea (Phase 2)
Electromyography (Phase 2/Phase 3)
Endometriosis (Phase 2/Phase 3)
Epilepsy (Phase 2)
Exercise (Phase 2)
Feeding and Eating Disorders (Phase 3)
Fibromyalgia (Phase 4)
Gastrointestinal Diseases (Phase 1)
Glaucoma (Phase 2)
Glioblastoma (Phase 1)
Health Services for the Aged (Phase 1)
Healthy Volunteers (Phase 1)
Heart Disease Risk Factors (Early Phase 1)
Hepatitis C (Phase 2)
Hidradenitis Suppurativa (Phase 2)
HIV (Phase 2)
HIV Infections (Phase 2)
Hyperalgesia (Phase 2)
Hypotension (Phase 1)
Inflammatory Bowel Diseases (Phase 2)
Low Back Pain (Phase 3)
Lung Neoplasms (Phase 1)
Marijuana Abuse (Phase 2)
Marijuana Smoking (Phase 2)
Marijuana Use (Phase 2)
Medical Oncology (Phase 2/Phase 3)
Migraine Disorders (Phase 2)
Motor Neuron Disease (Phase 2/Phase 3)
Mouth Neoplasms (Phase 1)
Multiple Sclerosis (Phase 3)
Muscle Spasticity (Phase 3)
Myofascial Pain Syndromes (Phase 2/Phase 3)
Nausea (Phase 2)
Neck Pain (Phase 3)
Neoplasms (Phase 3)
Neuralgia (Phase 3)
Neuralgia, Postherpetic (Phase 1/Phase 2)
Nicotine (Phase 1)
Obesity (Phase 2)
Obsessive-Compulsive Disorder (Phase 1/Phase 2)
Opiate Overdose (Phase 2)
Opioid-Related Disorders (Phase 2)
Osteoarthritis, Knee (Phase 2)
Pain (Phase 3)
Pain, Postoperative (Phase 3)
Pain Threshold (Phase 2)
Palliative Care (Phase 2/Phase 3)
Paraplegia (Phase 3)
Parkinson Disease (Phase 2)
Pelvic Pain (Phase 2/Phase 3)
Peripheral Nerve Injuries (Phase 3)
Peripheral Nervous System Diseases (Phase 3)
Phantom Limb (Phase 3)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 1)
Phobia, Social (Phase 2)
Protein-Energy Malnutrition (Phase 3)
Psoriasis (Phase 1)
Psychotic Disorders (Phase 1)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Quality of Life (Phase 2/Phase 3)
Reflex Sympathetic Dystrophy (Phase 1/Phase 2)
Renal Dialysis (Phase 3)
Respiratory Insufficiency (Phase 4)
Retinal Degeneration (Early Phase 1)
Retinitis Pigmentosa (Early Phase 1)
Safety (Phase 1)
Schizophrenia (Phase 1)
Sciatica (Phase 1/Phase 2)
Seizures (Phase 2)
Severe Acute Respiratory Syndrome (Phase 2)
Sleep Disorders, Intrinsic (Phase 2)
Sleep Wake Disorders (Phase 2)
Smoking (Early Phase 1)
Spinal Cord Diseases (Phase 2/Phase 3)
Spinal Cord Injuries (Phase 2/Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 3)
Substance-Related Disorders (Phase 1)
Tachycardia (Phase 1)
Temporomandibular Joint Disorders (Phase 2/Phase 3)
Tinnitus (Phase 1)
Tobacco Use (Phase 2)
Tourette Syndrome (Phase 2)
Traumatology (Phase 3)
Vaping (Phase 2)
Vomiting (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
